Esperion Therapeutics (NASDAQ:ESPR) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Friday.
Other research analysts also recently issued research reports about the company. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $94.00 price objective (up previously from $81.00) on shares of Esperion Therapeutics in a research note on Wednesday, February 21st. UBS Group set a $90.00 price objective on Esperion Therapeutics and gave the company a “neutral” rating in a research note on Wednesday, February 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $65.00 price objective (up previously from $55.00) on shares of Esperion Therapeutics in a research note on Wednesday, February 21st. Bank of America raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective for the company in a research note on Friday, January 5th. Finally, Chardan Capital upped their price objective on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, December 6th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $87.36.
Esperion Therapeutics (NASDAQ ESPR) opened at $75.26 on Friday. Esperion Therapeutics has a 52 week low of $20.39 and a 52 week high of $82.68.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the completion of the sale, the director now owns 3,177 shares of the company’s stock, valued at approximately $228,076.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.50% of the company’s stock.
Several hedge funds have recently made changes to their positions in ESPR. Millennium Management LLC grew its position in shares of Esperion Therapeutics by 1,062.7% during the 4th quarter. Millennium Management LLC now owns 387,947 shares of the biopharmaceutical company’s stock worth $25,542,000 after buying an additional 354,580 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $12,583,000. BNP Paribas Arbitrage SA grew its position in shares of Esperion Therapeutics by 12,603.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock worth $10,098,000 after buying an additional 199,890 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $9,517,000. Finally, MUFG Securities EMEA plc acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $9,022,000. 91.69% of the stock is owned by institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.